GoHealth
Auto Added by WPeMatico
Auto Added by WPeMatico
Welcome to The Exchange, an upcoming weekly newsletter featuring TechCrunch and Extra Crunch reporting on startups, money and markets. You can sign up for it here to receive it regularly when it launches on July 25th, and catch up on prior editions of the column and newsletter here.
It’s Saturday, July 18, and this is The Exchange. Today we’re wrapping our look at second-quarter VC, capping off the recent IPOs of some venture-backed startups, and digging into the hottest VCs while peeking at a new startup trend.
As July rubs along we’re getting deeper into the third quarter of 2020, meaning it’s time to close the books on Q2. To that end The Exchange combed through all the second-quarter VC data that we could this week.
But, despite working to grasp the health of the global venture scene, the United States’ own venture capital totals, and diving more deeply into AI/ML startups and how women-founded startups fundraised in Q2, there’s still more data to sift.
Keeping brief as we are a bit charted-out, New York City-based venture capital group Work-Bench released a grip of numbers detailing the city’s enterprise-focused startups’ Q2 VC results. Given that Work-Bench invests in enterprise tech, the data’s focus was not a surprise.
The numbers, per the firm, look like this:
The data is not surprising. B2B startups are raking in a larger share of venture capital rounds as time goes along, so to see NYC’s own enterprise-focused startups doing well is not shocking. (And if you add in the recent $225 million UIPath round, the Big Apple’s enterprise startups are even closer to their 2019 venture dollar benchmark, though the UIPath deal came in Q3.)
One last bit of data and we are done. Fenwick & West, a law firm that works with startups, released a report this week concerning Silicon Valley’s own May VC results. Two data points in particular from the digest stood out. Chew on these (emphasis TechCrunch):
The percentage of up-rounds declined modestly from 71% in April to 67% in May, but continued [to be] noticeably lower than the 83% up-rounds on average in 2019. […] The average share price increase of May financings weakened noticeably, declining from 63% in April to 43% in May. The results for both April and May were significantly below the 2019 average increase of 93%.
The Q2 data mix then shakes out to be better than I would have expected with plenty of highlights. But if you look, it isn’t hard to find weaker points, either. We are, after all, in the midst of a pandemic.

nCino and GoHealth went public this week. TechCrunch got on the blower afterwards with nCino CEO Pierre Naudé and GoHealth CEO Clint Jones. By now you’ve seen the pricing pieces and notes on their companies’ early performance, so let’s instead talk about why they chose to pursue traditional IPOs.
Our goal was to understand why CEOs are going public through initial public offerings when some players in the venture space have soured on traditional IPOs. Here’s what we gleaned from the leaders of the week’s new offerings:
nCino: Naudé didn’t want to dig into nCino’s IPO process, but did note that he read TechCrunch’s coverage of his company’s IPO march. The CEO said that his firm was going to have an all-hands this Friday, and then get back to work. Naudé also said that becoming a public company could help the nCino brand by helping others understand the company’s financial stability. The company’s larger-than-expected IPO haul (one point for the old-fashion public offering, we suppose) could provide it with more options, we learned, including possibly upping its sales and marketing spend.
GoHealth: Jones told TechCrunch that GoHealth’s IPO was oversubscribed, implying good pre-IPO demand. When it came to pricing, GoHealth worked through a number of scenarios according to the CEO, who didn’t have anything negative to share about how his company finally set its IPO valuation. He did bring up the importance of collecting long-term investors.
The method by which a company goes public is only a piece of the public-markets saga that companies spin. Once public, either through a direct listing or SPAC-led reverse-IPO, all companies become lashed to the quarterly reporting cycle. Even more common than complaints about the IPO process among Silicon Valley is the refrain that public investors are too short-term-focused to let really innovative companies do well once they stop being private.
Is that true? TechCrunch spoke with Medallia CEO Leslie Stretch this week to get notes on the current level of patience that public investors have for growing tech companies; are public markets as impatient as some claim?
According to Stretch, there can be enough space in the public markets for tech shops to maneuver. At least that was his take a year after Medallia’s own 2019 IPO (transcript edited by TechCrunch for clarity; additions denoted by brackets):
[Our] partnership with public investors has been phenomenal. They really test you, you know? They really test your proposition, [and] they test your operational resilience in a way that just makes you better. And they give you feedback. Our philosophy is feedback always makes you better.
What people want to do is they want to crest the really big growth rate [that] is unassailable, it can’t be challenged. And then you come out in public, and it’s a no brainer. And some companies managed to do that. But of the [thousands of Series] A rounds that took place in early 2000s, you know, only 75 companies made it public. Right? We’re one of them.
I’m not fearful. I don’t think people should be fearful of [going public]. They should partner with public investors. The stock price, and the quarter-to-quarter, will be what it will be. Don’t worry about that. It’s what are you building for the long term, and make sure you have enough cash, of course, to meet your ambitions. [But] also a bit of fiscal discipline actually makes your products better, because you think how about how you invest, and harder about your priorities. That’s my view on [the] public piece.
Who wants to bet that unicorns keep putting off their IPOs anyways?

Let’s wrap with some fun stuff, kicking off with the TechCrunch List, a dataset that set out to figure out which VCs were the most likely to cut first checks. I’ve already used it to help put together an investor survey (stay tuned). It’s in front of the Extra Crunch paywall, so give it a whirl.
If you are part of Extra Crunch, Danny also pulled out an even more exclusive list that we built off the back of thousands of founder comments.
And I have two trends for you to think on. First, a wave of startups are trying to make our new, video-chatting based world a better place to be. It will be super interesting to see how much space is left in the market by the incumbent players currently battling for market leadership.
Second, some startups are raising extension rounds not only because they need defensive capital, but because they’ve caught a tailwind in the COVID era and want to go even faster. So, from a somewhat safe move, some extension rounds these days are more weapons than shields.
And that’s all we have. Say hi on Twitter if there’s something you want The Exchange to explore. Chat soon!
Powered by WPeMatico
Hello and welcome back to Equity, TechCrunch’s venture capital-focused podcast, where we unpack the numbers behind the headlines.
This week was full of news of all sorts, but as we recorded, both Danny and Natasha “not Tash” Mascarenhas were still locked out of their Twitter accounts after a proletariat revolution on the social platform saw the ruling Blue Checkmark Class forced into silence. That’s not really what happened, but it sounds better than what actually went down at Big Social.
Anyway, Twitter accounts or not, the three of us gathered to parse through a wave of news:
It was a lovely time and there is a bit of show news. Namely that Equity is coming back to YouTube either this week or the next. So if you want to see us talk, soon you will be able to! Again!
Oh, and follow the show on Twitter. If you can, that is.
Equity drops every Monday at 7:00 a.m. PT and Friday at 6:00 a.m. PT, so subscribe to us on Apple Podcasts, Overcast, Spotify and all the casts.
Powered by WPeMatico
On the heels of nCino’s blockbuster debut, GoHealth’s public offering proved a more sedate affair, at least when comparing the two companies’ initial trading days.
GoHealth priced above its anticipated IPO range, selling more shares than initially planned in the process. By vending 43.5 million shares at $21 apiece — $1 per share more than the top of its preceding $18 to $20 range, and four million shares more than its target of 39.5 million — the insurance technology company put more than $900 million onto its balance sheet this week.
The debut is a win for Chicago’s industry and tech scenes. GoHealth was worth a little less than $6.7 billion at its IPO price, not counting shares that may be sold to its underwriters, which would boost its valuation.
Despite its better-than-anticipated pricing, however, GoHealth shares sagged in afternoon trading, slipping to $19.00 per share, down 9.5% as of the time of writing. The declines stand in contrast to the recent debuts of nCino, Lemonade and others, which saw their shares instantly gain value after going public.
GoHealth’s CEO, however, stressed the long-term vision of his company in an interview with TechCrunch. Speaking with Clint Jones during GoHealth’s first trading day, the executive told TechCrunch that his company’s offering was oversubscribed, and had met its goal of accumulating long-term investors during its IPO process.
The company intends to hire with its new funds, including 1,000 more licensed insurance agents, the CEO said.
Asked whether the company has plans to acquire smaller companies with its IPO funds, Jones told TechCrunch that it could be “opportunistic” regarding buying tech platforms, or smaller teams with particular talent. For the many startups competing in other parts of the insurance marketplace world — TechCrunch has covered the space extensively, including a bevy of funding rounds for insurtech startups — a newly wealthy public company could provide an interesting exit opportunity.
The company’s strong IPO pricing, if somewhat slack first-day’s trading, feels akin to a wash for related, smaller firms watching its public offering with interest; how GoHealth trades moving forward could help set the tone for select insurtech startup valuations.
For today, however, we have yet another unicorn tech-ish offering all wrapped up. GoHealth’s path to the public market’s wasn’t as straightforward as some, but it got there all the same.
Powered by WPeMatico